Somatostatin receptor (SSTR) imaging using PET has replaced scintigraphic imaging using
111In-pentetreotide (OctreoScan), unless PET is unavailable. Several benefits of SSTR PET …

Somatostatin receptor (SSTR) imaging is widely used for guiding the management of
neuroendocrine tumor (NET) patients. 68Ga-DOTATATE approval by the US Food and Drug …

Somatostatin receptor (SSTR) PET has demonstrated a significant improvement over
conventional imaging (CI) in patients with neuroendocrine tumors (NETs). SSTR PET should …

Studies demonstrate that the investigational 64Cu-DOTATATE radiopharmaceutical may
provide diagnostic and logistical benefits over available imaging agents for patients with …

A new era of precision diagnostics and therapy for patients with neuroendocrine neoplasms
began with the approval of somatostatin receptor (SSTR) radiopharmaceuticals for PET …

Somatostatin receptor imaging is a valuable tool in the diagnosis, follow-up, and treatment
planning of neuroendocrine tumor (NET). PET-based tracers using 68Ga as the radioisotope …

Reliable standards and criteria for somatostatin receptor (SSTR) PET are still lacking. We
herein propose a structured reporting system on a 5-point scale for SSTR PET imaging, titled …

Imaging of somatostatin receptor expression is an established technique for staging of
neuroendocrine neoplasia and determining the suitability of patients for peptide receptor …

Opinion statement Neuroendocrine tumors (NETs) are relatively rare, with 12,000–15,000
new cases diagnosed annually in the USA. Although NETs are a diverse group of …

Neuroendocrine tumors (NETs) are rare neoplasms characterized by overexpression of
somatostatin receptors (SSTRs). Functional imaging plays a crucial role in management of …